Mitochondrial transplantation therapy for heart failure

Image Credit: ART-ur / Shutterstock.com
Extracellular vesicles delivering functional mitochondria directly to damaged cardiomyocytes.
About the Technology
Heart failure remains a leading cause of morbidity and mortality worldwide, with limited options for patients in advanced stages.
Our innovative therapy utilizes extracellular vesicles from universal donor cells, engineered to deliver functional mitochondria directly to damaged cardiomyocytes, addressing the underlying cellular dysfunction rather than just symptoms. We have demonstrated efficacy in a preclinical pig model of chronic heart failure utilizing a catheter-mediated minimally invasive approach.
During the HIT Fund program, we aim to optimize dosage, conduct FDA-compliant safety trials, and investigate the durability of therapeutic effects, paving the way for regulatory submissions and clinical applications.
Team Members

Yasuhiro Shudo
Clinical Assistant Professor, Cardiothoracic Surgery - Adult Cardiac Surgery